C

Cencora

Global pharmaceutical distribution and services provider

Pharmacist

Full-TimeUpdated on 10/5/2026
No salary listed
Entry, Junior, Mid
Bachelor's
Elizabethtown, PA, USA
In Person

About the job

Requirements
  • Requires a degree in Pharmacy from an accredited College of Pharmacy.
  • Requires an unrestricted, current state license as a Registered Pharmacist in the resident state.
  • Requires an active Pennsylvania pharmacist license.
  • Must obtain and maintain required non-resident state licenses as business needs dictate to support multi-state operations and customer service.
  • Ability to communicate effectively both orally and in writing.
  • Ability to work quickly and accurately under time and volume constraints.
  • Strong leadership skills.
  • Strong interpersonal skills.
  • Ability to resolve customer issues quickly and creatively to improve customer satisfaction.
  • Familiarity with pharmaceutical products, services, and drug interactions.
  • Strong organizational skills and attention to detail.
  • Good analytical skills.
  • Knowledge of Microsoft Word, Excel, PowerPoint, and Outlook.
Responsibilities
  • Deliver pharmacy support and operations assignments independently, managing scope, quality, and timelines with minimal guidance.
  • Apply practical knowledge of pharmacy operations across varied tasks while maintaining awareness of upstream and downstream workflow impacts.
  • Communicate within the function and with select partners to confirm requirements, Service Level Agreements, and handoffs.
  • Solve problems using established methods and recommend and implement process improvements within approved change controls.
  • Make independent decisions guided by experience and policy, escalating novel risks or cross-team trade-offs as appropriate.
  • Obtain valid prescription information from a licensed veterinarian or designated agent before dispensing.
  • Initiate and receive calls and faxes for medication orders.
  • Clarify medication orders when needed.
  • Dispense medications according to prescriptions from licensed veterinarians.
  • Prepare medication for end-user use according to current veterinary pharmacy standards of practice.
  • Ensure medications are appropriately labeled and products are delivered to end-users in a timely, safe, and efficient manner.
  • Answer appropriate questions from other healthcare providers and end-users regarding medication and approved usage.
  • Maintain records of all drugs dispensed and prescriptions filled.
  • Prepare required reports, including daily dispensing logs and monthly usage reports.
  • Ensure drug products in the pharmacy are stored under appropriate conditions.
  • Maintain a high standard of customer service.
  • Provide backup service for other pharmacies as needed.
  • Cross-train across pharmacy operational functions and perform tasks including inventory replenishment, wave orders, prescription entry, pick/tote orders, order entry, e-filing in SharePoint, WMS inventory/order control, clinic/CER communication, resolving order issues, packing and closing orders, printing prescriptions from SharePoint, and canceling orders in WMS as applicable.
  • Perform related duties as assigned.

About the company

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 Q3 revenue rose 5.1% to $84.8 billion; EPS beat estimates.
  • Cencora repurchased $1 billion shares in Q3 2026 and raised fiscal 2026 guidance.
  • June 17 and September 2, 2026 launches expand high-growth specialty and cell-therapy services.

What critics are saying

  • March 31, 2026 accrued opioid liability remained $4.3 billion, payable over 13 years.
  • Baltimore’s October 2025 verdict was vacated in April 2026, but opioid litigation persists.
  • ASP rule changes and specialty-logistics competition can compress margins and derail oncology economics.

What makes Cencora unique

  • Cencora embeds inside oncology through OneOncology and RCA, strengthening provider switching costs.
  • June 17, 2026 Nucleus and September 2, 2026 CGT Enablement deepen workflow integration.
  • Global distribution scale and specialty services create a rare pharma-plus-services moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.